Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

3212 results about "Ecg signal" patented technology

Contrast agent imaging with destruction pulses in diagnostic medical ultrasound

The invention is directed to improvements in diagnostic medical ultrasound contrast agent imaging. In a preferred embodiment, high pulse repetition frequency (HPRF) destruction pulses are fired at a rate higher than necessary for receiving returning echoes. Pulse parameters can also be changed between the plurality of contrast agent-destroying pulses. Other preferred embodiments of the invention are directed to simultaneous transmission of multiple beams of destruction pulses. Destruction frames that consist of a plurality of destruction pulses can be triggered and swept over the entire region of tissue being imaged and at a variety of focal depths from the transmitter. The destruction frames are fired at some time triggered from a timer or some fixed part of a physiological signal, such as an ECG signal. Other preferred embodiments of the invention are directed to continuous low power imaging pulses alternating with destruction pulses triggered at a fixed point of a physiological signal, and a comparison of the received signals from imaging pulses fired before and after the destruction pulses. Alternatively, destruction pulses are triggered at a fixed point on a physiological signal different from the fixed point of a physiological signal used to trigger imaging pulses. In another embodiment, triggered destruction frames are used to enable a comparison of imaging frames in order to determine physiological functions, such as perfusion of blood in cardiac tissue. Finally, in another embodiment, destruction pulses are combined with subharmonic imaging.
Owner:SIEMENS MEDICAL SOLUTIONS USA INC

Method and apparatus for monitoring drug effects on cardiac electrical signals using an implantable cardiac stimulation device

An implantable cardiac stimulation device, such as a pacemaker or Implantable Cardioverter Defibrillator, is configured to automatically monitor the effects of antiarrhythmic drugs on cardiac electrical signals within a patient to verify the efficacy of the drugs taken. In one example, an analysis of patient cardiac electrical signals is performed by comparing the cardiac electrical signals with values representative of the effects of different classes of antiarrhythmic drugs. If the implantable device determines that the prescribed antiarrhythmic drugs have not been effective, a warning signal is generated. The warning signal is conveyed directly to the patient via a bedside monitor and to the patient's physician via remote connection to an external programmer device so that both are notified of the drug efficacy problems. Additionally, the implantable device may be configured to automatically adjust pacing and defibrillation control parameters in an attempt to compensate for any lack of efficacy in the drugs. For example, the aggressiveness of overdrive pacing may be increased. Alternatively, a drug pump is controlled to adjust the dosage of antiarrhythmic drugs if an initial dosage is found to be ineffective.
Owner:PACESETTER INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products